

## DAFTAR PUSTAKA

1. Ogawa R. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis. *Int J Mol Sci*. 2017;(18(606)):1–10.
2. Huang C, Wu Z, Du Y, Ogawa R. The Epidemiology of Keloids [Internet]. Téot; 2020. p. 29–34. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK586088/>
3. Listiawan MY, Murtiastutik D, Sandhika W, Rachmantyo B, Wardhani PH. Comparison between fractional Co2 laser-triamcinolone injection combination therapy and triamcinolone injection monotherapy for keloid. Vol. 11, *Dermatology Reports*. 2019.
4. Andisi RDS, Suling PL, Kapantow MG. Profil keloid di Poliklinik Kulit dan Kelamin RSUP Prof. Dr. R. D. Kandou Manado periode Januari 2011-Desember 2015. *e-CliniC* [Internet]. 2016 [cited 2024 Feb 17];4(2). Available from: <https://ejournal.unsrat.ac.id/v3/index.php/eclinic/article/view/14667>
5. Odilia C. Profil Keloid Pada Pasien Rsup Dr. M. Djamil Padang Tahun 2016- 2020 pada RSUP Dr M. Djamil Padang Tahun 2016-2020 [Internet] [Skripsi]. [Padang]: Universitas Andalas; 2021 [cited 2024 Feb 15]. Available from: <http://scholar.unand.ac.id/74928/>
6. Choirunanda A, I P. Profil Gangguan Kualitas Hidup Akibat Keloid Pada Mahasiswa Fakultas Kedokteran Universitas Udayan Angkatan 2012-2014. *J Med Udayan*. 2019;(8).
7. Kassi K, Kouame K, Kouassi A, Allou A, Kouassi I, Kourouma S, et al. Quality of life in black African patients with keloid scars. Vol. 12, *Dermatology Reports*. 2020. p. 28–31.
8. Shaheen A. Comprehensive Review of Keloid Formation. *Clin Res Dermatol Open Access*. 2019;4(5):1–18.
9. Udayan B, Travis W. B. Keloids: A Review of Etiology, Prevention, and Treatment. *J Clin Aesthet Dermatol*. 2020;13(2):43.
10. Unahabhokha T, Sucontphunt A, Nimmannit U, Chanvorachote P, Yongsanguanchai N, Pongrakhananon V. Molecular signalings in keloid disease and current therapeutic approaches from natural based compounds. Vol. 53, *Pharmaceutical Biology*. 2015. p. 457–63.
11. Arno AI, Gauglitz GG, Barret JP, Jeschke MG. Up-to-date approach to manage keloids and hypertrophic scars: A useful guide. Vol. 40, *Burns*. 2014. p. 1255–66.
12. Perdanasari AT, Lazzeri D, Su W, Xi W, Zheng Z, Ke L, et al. Recent developments in the use of intralesional injections keloid treatment. Vol. 41, *Archives of Plastic Surgery*. 2014. p. 620–9.
13. Thornton NJ, Garcia BA, Hoyer P, Wilkerson MG. Keloid Scars: An Updated Review of Combination Therapies. *Cureus*. 2021;
14. Ashcroft KJ, Syed F, Bayat A. Site-specific keloid fibroblasts alter the behaviour of normal skin and normal scar fibroblasts through paracrine signalling. *PloS one* [Internet]. 2013 [cited 2024 Feb 16];8(12):e75600. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0075600>
15. Trace AP, Enos CW, Mantel A, Harvey VM. Keloids and Hypertrophic Scars: A Spectrum of Clinical Challenges. Vol. 17, *American Journal of Clinical Dermatology*. 2016. p. 201–23.
16. Tuan TL, Wu H, Huang EY, Chong SSN, Laug W, Messadi D, et al. Increased plasminogen activator inhibitor-1 in keloid fibroblasts may account for their elevated

- collagen accumulation in fibrin gel cultures. *Am J Pathol* [Internet]. 2003;162(5):1579–89. Available from: [http://dx.doi.org/10.1016/S0002-9440\(10\)64292-7](http://dx.doi.org/10.1016/S0002-9440(10)64292-7)
17. Garside SB, McGrouther E, Bayat DA, Ardeshir. Molecular dissection of abnormal wound healing processes resulting in keloid disease. *Wound Repair and Regen.* 2009;18(2):139–53.
  18. Suryono. Potensi Teh Hijau Dalam Penyembuhan Luka: Sistemik Review. *Pros Konf Nas PPNI Jawa Teng.* 2013:202–2025.
  19. Mehta M, Branford O. The evidence for natural therapeutics as potential anti-scarring agents in burn-related scarring. *Burn Trauma.* 2016;4.
  20. Park G, Yoon BS, Moon J-H, Kim B, Jun EK, Oh S, et al. Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in. *J Invest Dermatol.* 2008;128(10):2429–41.
  21. Kurniatri AA, Sulistyaningrum N, Rustanti L. Purifikasi katekin dari ekstrak gambir (*Uncaria gambir* Roxb.). *Media Penelitian Dan Pengembangan Kesehatan* [Internet]. 2019 [cited 2024 Feb 16];29(2):153–60. Available from: <https://www.academia.edu/download/66515224/1070.pdf>
  22. Rahmawati N, Bakhtiar A, Putra P. Isolasi Katekin dari Gambir (*Uncaria gambir* (Hunter). Roxb) untuk Sediaan Farmasi dan Kosmetik. *J Penelit Farm Indones.* 2012;1(1):6–10.
  23. Amos. The Gambier Catechin Content of Production Centers in Indonesia. *J Stand.* 2017;12:149–55.
  24. Indah IS. Pengaruh Katekin Gambir (*Uncaria Gambir* Roxburgh) Terhadap Proliferasi Dan Migrasi Sel Fibroblas Keloid [Internet] [Thesis]. Fakultas Kedokteran Universitas Andalas; 2021 [cited 2024 Feb 16]. Available from: <http://scholar.unand.ac.id/74353/>
  25. Prabowo Y. Pengaruh Ekstrak Katekin Gambir (*Uncaria Gambir* Roxburgh) Terhadap Jumlah Kolagen Keloid (In Vitro) [Internet] [Thesis]. Fakultas Kedokteran Universitas Andalas; 2022 [cited 2024 Feb 16]. Available from: <http://scholar.unand.ac.id/107988/>
  26. Darby IA, Desmoulière A. Scar Formation: Cellular Mechanisms. 2020. p. 19–26.
  27. McGinty S SWK. Keloid [Internet]. [Updated 2021 Jul 24]. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. 2022. Available from: [https://www.ncbi.nlm.nih.gov/books/NBK507899/#\\_NBK507899\\_pubdet\\_](https://www.ncbi.nlm.nih.gov/books/NBK507899/#_NBK507899_pubdet_)
  28. Rachmantyo B, Listiawan MY, Murtiastutik D, Sandhika W, Staf D, Fungsional M, et al. Perbandingan Terapi Kombinasi Laser CO2-Injeksi Triamsinolon dengan Injeksi Triamsinolon Monoterapi pada Keloid. Vol. 30, *Berkala Ilmu Kesehatan Kulit dan Kelamin.* 2018. p. 128.
  29. Odilia CPK. Profil Keloid Pada Pasien Rsup Dr. M. Djamil Padang Tahun 2016- 2020 pada RSUP Dr M. Djamil Padang Tahun 2016-2020. Universitas Andalas; 2021.
  30. Limandjaja GC, Niessen FB, Scheper RJ, Gibbs S. The Keloid Disorder: Heterogeneity, Histopathology, Mechanisms and Models. Vol. 8, *Frontiers in Cell and Developmental Biology.* 2020.
  31. Khoo YT, Ong CT, Mukhopadhyay A, Han HC, Do DV, Lim IJ, et al. Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. *Journal Cellular Physiology* [Internet]. 2006 Aug [cited 2024 Feb 16];208(2):336–43. Available from: <https://onlinelibrary.wiley.com/>
  32. Marneros AG, Krieg T. Keloids--clinical diagnosis, pathogenesis, and treatment options. *J Dtsch Dermatol Ges.* 2004;2:905.
  33. Campaner AB, Cusik J, Bruder J, Sobral C, Morgan J, Filho AG, et al. Upregulation of TGF- $\beta$ 1 expression may be necessary but is not sufficient for excessive scarring. Vol. 33, *Burns.* 2007. p. S124.

34. Fujiwara M, Muragaki Y, Ooshima A. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. Vol. 153, *British Journal of Dermatology*. 2005. p. 295–300.
35. Ghazawi FM, Zargham R, Gilardino MS, Sasseville D, Jafarian F. Insights into the Pathophysiology of Hypertrophic Scars and Keloids: How Do They Differ? Vol. 31, *Advances in Skin and Wound Care*. 2018. p. 582–95.
36. Al-Attar A, Mess S, Thomassen JM, Kauffman CL, Davison SP. Keloid pathogenesis and treatment. Vol. 117, *Plastic and Reconstructive Surgery*. 2006. p. 286–300.
37. Akaishi S, Ogawa R, Hyakusoku H. Visual and pathologic analyses of keloid growth patterns. Vol. 64, *Annals of Plastic Surgery*. 2010. p. 80–2.
38. Ali SS, Hajrah NH, Ayuob NN, Moshref SS, Abuzinadah OA. Morphological and morphometric study of cultured fibroblast from treated and untreated abnormal scar. Vol. 31, *Saudi Medical Journal*. 2010. p. 874–81.
39. Shang T, Yao B, Gao D, Xie J, Fu X, Huang S. A novel model of humanised keloid scarring in mice. Vol. 15, *International Wound Journal*. 2018. p. 90–4.
40. Shin JU, Kim SH, Kim H, Noh JY, Jin S, Park CO, et al. TSLP Is a Potential Initiator of Collagen Synthesis and an Activator of CXCR4/SDF-1 Axis in Keloid Pathogenesis. Vol. 136, *Journal of Investigative Dermatology*. 2016. p. 507–15.
41. Robles DT, Erin Moore MD, Berg D. Keloids: pathophysiology and management - PubMed. *Dermatol Online J*. 2017;13(3).
42. Sidle DM, Kim H. Keloids: prevention and management. *Facial Plast Surg Clin*. 2011;19(3):50.
43. Ardehali B, Nouraei SAR, Van Dam H, Dex E, Wood S, Nduka C. Objective assessment of keloid scars with three-dimensional imaging: Quantifying response to intralesional steroid therapy. Vol. 119, *Plastic and Reconstructive Surgery*. 2007. p. 556–61.
44. Kim SW. Management of keloid scars: Noninvasive and invasive treatments. Vol. 48, *Archives of Plastic Surgery*. 2021. p. 149–57.
45. Dalkowski A, Fimmel S, Beutler C, Zouboulis CC. Cryotherapy modifies synthetic activity and differentiation of keloidal fibroblasts in vitro. Vol. 12, *Experimental Dermatology*. 2003. p. 673–81.
46. Limmer EE, Glass DA. A Review of Current Keloid Management: Mainstay Monotherapies and Emerging Approaches. Vol. 10, *Dermatology and Therapy*. 2020. p. 931–48.
47. Surgery R, Clinic WT. Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars : Retrospective study of ... 2014.
48. Garg MK, Weiss P, Sharma AK, Gorla GR, Jaggernaut W, Yaparpalvi R, et al. Adjuvant high dose rate brachytherapy (Ir-192) in the management of keloids which have recurred after surgical excision and external radiation. Vol. 73, *Radiotherapy and Oncology*. 2004. p. 233–6.
49. Tanzi EL, Alster TS. Laser treatment of scars. Vol. 9, *Skin therapy letter*. 2004. p. 4–7.
50. Kuo YR, Wu WS, Jeng SF, Huang HC, Yang KD, Sacks JM, et al. Activation of ERK and p38 kinase mediated keloid fibroblast apoptosis after flashlamp pulsed-dye laser treatment. Vol. 36, *Lasers in Surgery and Medicine*. 2005. p. 31–7.
51. Kuo Y-R, Wu W-S, Jeng S-F, Wang F-S, Huang H-C, Lin C-Z, et al. Suppressed TGF-beta1 expression is correlated with up-regulation of matrix metalloproteinase-13 in k. *Lasers Surg Med*. 2005;36:38–42.
52. O'Brien L, Jones DJ. Silicone gel sheeting for preventing and treating hypertrophic and

- keloid scars. Cochrane database of systematic reviews [Internet]. 2013 [cited 2024 Feb 16];(9). Available from: <https://www.cochranelibrary.com/cdsr/10.1002/14651858.CD003826.pub3/abstract>
53. Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: Pathomechanisms and current and emerging treatment strategies. Vol. 17, *Molecular Medicine*. 2011. p. 113–25.
  54. Tan S NK, A B. Understanding Keloid Pathobiology From a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease With Cancer-Like Tendencies. *Front Immunol*. 2019;10:1–15.
  55. Ud-Din S, Wilgus TA, McGeorge DD, Bayat A. Pre-Emptive Priming of Human Skin Improves Cutaneous Scarring and Is Superior to Immediate and Delay. *MDPI*. 2021;1–37.
  56. Tsai CH, Ogawa R. Keloid research: current status and future directions. *Scars, Burns and Healing* [Internet]. 2019 Jan [cited 2024 Feb 15];5:1–8. Available from: <http://journals.sagepub.com/>
  57. Kontochristopoulos G, Stefanaki C, Panagiotopoulos A, Stefanaki K, Argyrakos T, Petridis A, et al. Intralesional 5-fluorouracil in the treatment of keloids: an open clinical and histopathologic study. Vol. 52, *Journal of the American Academy of Dermatology*. 2005. p. 474–9.
  58. Gauglitz GG. Management of keloids and hypertrophic scars: Current and emerging options. Vol. 6, *Clinical, Cosmetic and Investigational Dermatology*. 2013. p. 103–14.
  59. Davison SP, Mess S, Kauffman LC, Al-Attar A. Ineffective treatment of keloids with interferon alpha-2b. Vol. 117, *Plastic and Reconstructive Surgery*. 2006. p. 247–52.
  60. Hera N, Aprelia R, Aminuddin AT. Eksplorasi Dan Karakteristik Morfologi Tanaman Gambir Liar (*Uncaria Gambir Roxb*) Pada Lahan Gambut Dataran Rendah Di Kota Pekanbaru Exploration And Morphological Characteristic Wild Gambir (*Uncaria Gambir Roxb* .) Of Lowland Peatlands In Pekanbaru City. 2020;XIV(02):68–72.
  61. Anggraini T, . N, Asben A. Mangampo: A Traditional Method from West Sumatra to Extract Gambir from *Uncaria gambir*. *Pakistan J Nutr*. 2019;18(2):146–52.
  62. Sebayang L, Afni Hardyani M. The Morphology Characteristics of Plant Gambir (*Uncaria gambire Roxb.*) in Pakpak Barat District. *J Pertan Trop*. 2020;7(2):213–8.
  63. Munggar IP, Kurnia D, Deawati Y, Julaeha E. Current Research of Phytochemical, Medicinal and Non-Medicinal Uses of *Uncaria gambir Roxb.*: A Review. Vol. 27, *Molecules*. 2022.
  64. Latos-Brozio M, Masek A. Structure-Activity Relationships Analysis of Monomeric and Polymeric Polyphenols (*Quercetin, Rutin a*. *Chem Biodivers*. 2019;16(12).
  65. Wang J, Tang H, Hou B, Zhang P, Wang Q, Zhang BL, et al. Synthesis, antioxidant activity, and density functional theory study of catechin derivatives. *RSC Adv*. 2017;7(85):54136–41.
  66. Patel S, Faraj Y, Duso DK, Reiley WW, Karlsson EA, Schultz-Cherry S, et al. Comparative safety and efficacy profile of a novel oil in water vaccine adjuvant comprising vitamins A and E and a catechin in protective anti-influenza immunity. Vol. 9, *Nutrients*. 2017.
  67. Shim W, Kim CE, Lee M, Lee SH, Park J, Do M, et al. Catechin solubilization by spontaneous hydrogen bonding with poly(ethylene glycol) for dry eye therapeutics. Vol. 307, *Journal of Controlled Release*. 2019. p. 413–22.
  68. Lakshmi SP, Reddy AT, Kodihela LD, Varadacharyulu NC. The tea catechin epigallocatechin gallate inhibits NF- $\kappa$ B-mediated transcriptional activation by covalent modification. Vol. 695, *Archives of Biochemistry and Biophysics*. 2020.

69. Park JS, Kim MH, Chang HJ, Kim KM, Kim SM, Shin BA, et al. Epigallocatechin-3-gallate inhibits the PDGF-induced VEGF expression in human vascular smooth muscle. *Int J Oncol.* 2006;29(5).
70. Farooqi AA, Pinheiro M, Granja A, Farabegoli F, Reis S, Attar R, et al. EGCG Mediated Targeting of Deregulated Signaling Pathways and Non-Coding RNAs in Different Cancers: *Cancers (Basel).* 2020;12(4):951.
71. Li T, Zhao N, Lu J, Zhu Q, Liu X, Hao F, et al. Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in a. *Bioengineered.* 2019;10(1):282–91.
72. Ningsih S. Efek hepatoprotektor gambir (*Uncaria gambir* (Hunter)Roxb.) dalam menghambat pembentukan kolagen dengan menekan TIMP-1 (Tissue inhibitor of metalloproteinase-1) *in vivo.* Universitas Indonesia; 2015.
73. Indonesia U, Kedokteran F, Indonesia U, Studi P, Ilmu D. Efek Fibropreventif Dan Fibrolisis Pemberian Gambir ( *Uncaria Gambir* ) Pada Fibrosis Paru Tikus Model. 2020; Available from: [https://eprints.untirta.ac.id/28397/1/Disertasi Desdiani Final- converted.pdf](https://eprints.untirta.ac.id/28397/1/Disertasi%20Desdiani%20Final-converted.pdf)
74. Desdiani D, Rengganis I, Djauzi S, Setiyono A, Sadikin M, Jusman SWA, et al. In vitro Assay and Study Interaction of *Uncaria gambir* (Hunter) Roxb. as Anti-fibrotic Activity Against A549 Cell Line. *Pharmacogn J.* 2020;12(6):1232–40.
75. Wu Y, Zhang Q, Ann DK, Akhondzadeh A, Duong HS, Messadi D V, et al. Increased vascular endothelial growth factor. *Am J Physiol Cell Physiol.* 2004;286(4).
76. Kondo T, Ohta T, Igura K, Hara Y, Kaji K. Tea catechins inhibit angiogenesis *in vitro*, measured by human endothelial cell growth, migration an. *Cancer Lett.* 2002;180(2).
77. Cai Y, Yu SS, Chen TT, Gao S, Geng B, Yu Y, et al. EGCG inhibits CTGF expression via blocking NF- $\kappa$ B activation in cardiac fibroblast. Vol. 20, *Phytomedicine.* 2013. p. 106–13.
78. Ud-Din S, Bayat A. Non-animal models of wound healing in cutaneous repair: *In silico*, *in vitro*, *ex vivo*, and *in vivo* models of wounds and scars in human skin. Vol. 25, *Wound Repair and Regeneration.* 2017. p. 164–76.
79. Revilla G. Buku monograf: sel punca mesenkimal untuk luka bakar. Padang: Andalas university press; 2019. p.17
80. Domingo DS, Camouse MM, Hsia AH, Matsui M, Maes D, Ward NL, et al. Anti- angiogenic effects of epigallocatechin-3-gallate in human skin. Vol. 3, *International Journal of Clinical and Experimental Pathology.* 2010. p. 705–9.